AVITA Medical is a therapeutic acute wound care company specializing in transformative solutions designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes. The company focuses on addressing critical healing needs arising from burns, traumatic injuries, and surgical repairs through a portfolio of proprietary and complementary products. Its technologies support wound bed preparation, definitive closure, and recovery, positioning it as a leader in acute wound management. AVITA Medical’s innovations are rooted in autologous cell harvesting and advanced wound matrices, catering to high-acuity medical settings.

The company generates revenue primarily through the sale of its proprietary wound care products, including RECELL, Cohealyx, and PermeaDerm. RECELL, its flagship product, is an autologous cell harvesting device approved for treating thermal burn wounds and full-thickness skin defects, with additional approval for repigmenting stable vitiligo lesions. Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix, complement RECELL by addressing wound bed preparation and coverage. Revenue is derived from direct sales to hospitals, burn centers, trauma centers, and surgical facilities, supported by established reimbursement mechanisms under Medicare and commercial payers.

The company operates through the following segments:

• Burn Care: This segment centers on the treatment of thermal burn wounds using RECELL, which enables clinicians to create a suspension of a patient’s own skin cells for wound healing. RECELL reduces donor skin requirements by up to 97.5% for second-degree burns and 32% for third-degree burns, improving clinical outcomes while lowering healthcare costs. The segment also includes RECELL GO and RECELL GO mini, next-generation devices designed for enhanced workflow efficiency and treatment of smaller wounds.

• Full-Thickness Skin Defects: This segment addresses traumatic injuries, surgical wounds, and oncologic excisions that result in full-thickness skin defects. RECELL is approved for these indications, allowing clinicians to achieve wound closure with reduced donor skin harvesting. The segment leverages the same commercial infrastructure as burn care, targeting trauma and surgical centers that share similar clinical and operational characteristics with burn centers.

• Complementary Wound Care Products: This segment includes Cohealyx and PermeaDerm, which support wound bed preparation and coverage. Cohealyx, a collagen-based dermal matrix, accelerates wound vascularization and readiness for grafting, while PermeaDerm, a biosynthetic wound matrix, provides transparent, flexible, and moisture-managing wound coverage. These products enhance the company’s comprehensive approach to acute wound management.

AVITA Medical holds a distinctive position in the acute wound care industry, with RECELL facing no direct competition as an autologous cell harvesting technology. Its primary indirect competitor is the traditional split-thickness autograft, the current standard of care for severe burns and full-thickness wounds. The company’s competitive advantages include clinically proven reductions in donor skin requirements, patient-reported pain, and hospital length of stay, alongside demonstrated health-economic benefits. Its expanding intellectual property portfolio, including patents and trademarks, further strengthens its market position. Regulatory approvals in the U. S., Europe, Australia, and Japan create significant barriers to entry for potential competitors, reinforcing its leadership in the space.

The company’s customer base consists primarily of specialized burn centers, trauma centers, and surgical facilities in the U. S. and internationally. In the U. S., approximately 140 burn centers treat the majority of severe burn patients, representing a core customer segment. With the expansion of RECELL’s indications to include full-thickness skin defects, AVITA Medical has broadened its reach to additional trauma and surgical centers that manage complex acute wounds. Internationally, the company relies on third-party distributors to commercialize its products in markets such as Europe, Australia, and Japan. Customers evaluate adoption through hospital value analysis committees, which assess clinical outcomes and total cost of care.